Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

9.050 -0.200 (-2.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,047,844
Open 8.430
Bid (Size) 9.020 (5)
Ask (Size) 9.090 (10)
Prev. Close 9.250
Today's Range 8.270 - 9.155
52wk Range 3.210 - 18.33
Shares Outstanding 279,832,722
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Iovance Biotherapeutics Stock Stumbled Today
One pundit warns of apparent manufacturing issues with the company's melanoma drug. 
Via The Motley Fool
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+11.73%
+11.73%
1 Month
+12.28%
+12.28%
3 Month
-24.77%
-24.77%
6 Month
+9.04%
+9.04%
1 Year
+24.66%
+24.66%

More News

Read More
Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy
Via Benzinga
Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.
Via The Motley Fool
Topics Economy
Exposures Interest Rates
How Is The Market Feeling About Iovance Biotherapeutics?
Via Benzinga
What's Going On With Iovance Biotherapeutics Today?
Via Benzinga
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys
Via InvestorPlace
Is Iovance Biotherapeutics a Millionaire Maker?
Via The Motley Fool
3 Under-$10 Biotech Stocks That Could Make You Rich
Via InvestorPlace
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Is It Too Late to Buy Iovance Biotherapeutics Stock?
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
3 Top Penny Stocks to Skyrocket Your Wealth in 2024
Via InvestorPlace
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
Via The Motley Fool
Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
Via News Direct
Exposures Product Safety
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.